Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease
2016; Massachusetts Medical Society; Volume: 374; Issue: 12 Linguagem: Inglês
10.1056/nejmoa1510926
ISSN1533-4406
AutoresFrederick E. Dewey, Viktoria Gusarova, Colm O’Dushlaine, Omri Gottesman, Jesus Trejos, Charleen Hunt, Cristopher V. Van Hout, Lukas Habegger, David G. Buckler, Ka-Man V. Lai, Joseph B. Leader, Michael F. Murray, Marylyn D. Ritchie, H. Lester Kirchner, David H. Ledbetter, John S. Penn, Alexander Lopez, Ingrid B. Borecki, John D. Overton, Jeffrey G. Reid, David J. Carey, Andrew Murphy, George D. Yancopoulos, Aris Baras, Jesper Gromada, Alan R. Shuldiner,
Tópico(s)Atherosclerosis and Cardiovascular Diseases
ResumoHigher-than-normal levels of circulating triglycerides are a risk factor for ischemic cardiovascular disease. Activation of lipoprotein lipase, an enzyme that is inhibited by angiopoietin-like 4 (ANGPTL4), has been shown to reduce levels of circulating triglycerides.
Referência(s)